ADMA Biologics Responds to Short Seller Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ADMA?
Source: Newsfilter
- Growing Demand: ADMA highlights that demand for ASCENIV has steadily increased over the past two years, with inventory levels aligning with industry standards, demonstrating the company's strong performance in the immunocompromised patient market.
- Effective Inventory Management: As of March 22, 2026, ASCENIV's average inventory days were 48, and BIVIGAM's were 51, indicating that distributors maintain safety stock levels sufficient to address potential supply chain disruptions and ensure continuity of care for patients.
- Clear Market Positioning: ASCENIV is positioned as a late-line therapy for immunocompromised patients, commanding premium pricing, and the short seller report's misunderstanding of its competitive positioning may affect market perception.
- Positive Audit Opinions: ADMA received unqualified opinions in its audits for FY 2024 and FY 2025, indicating the effectiveness of its financial reporting, which enhances investor confidence in the company's transparency and compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: On March 24, 2026, ADMA Biologics' shares fell over 16% following a report from short seller Culper Research, which accused the company of channel stuffing and undisclosed related party distributors, undermining investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into whether ADMA violated federal securities laws, urging investors who suffered significant losses to submit their information for potential legal action.
- Financial Transparency Concerns: Culper Research highlighted a dramatic increase in ADMA's days sales outstanding (DSO), which surged to 113 days by the end of 2025 from 43 days the previous year, indicating that the company may have inflated revenues by extending payment terms, thus questioning the integrity of its financial reporting.
- Market Reaction: The sharp decline in ADMA's stock price prompted an analyst downgrade from overweight to neutral, raising concerns about the company's future financial health and potentially impacting its ability to secure financing and grow its business.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the authenticity of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly inflated revenue figures; without this scheme, the company would have faced a 3% revenue decline in 2025.
- Stock Price Plunge: The news triggered a significant decline in ADMA's stock price, dropping $3.96 or 29% over two trading days, from $13.59 on March 23 to $9.63 on March 25, indicating market concerns about the company's financial health.
- Legal Options for Investors: Investors are encouraged to contact BFA for legal support, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: ADMA Biologics saw its shares plummet over 16% on March 24, 2026, following a report from Culper Research alleging channel stuffing and undisclosed related party distributors, which undermined investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into ADMA to determine if the company violated federal securities laws, particularly regarding the compliance of its financial reporting, urging investors who suffered significant losses to submit their information.
- Financial Transparency Issues: The Culper report highlighted a dramatic increase in ADMA's days sales outstanding (DSO) from 43 days in 2024 to 113 days in 2025, suggesting the company may have inflated revenues by inducing distributors to stockpile products, thus impacting the accuracy of its financial statements.
- Analyst Downgrade: The market reacted swiftly to Culper's allegations, resulting in a significant drop in ADMA's stock price and prompting an analyst downgrade from overweight to neutral, reflecting growing concerns about the company's financial health.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Launched: Kirby McInerney LLP is investigating potential violations of federal securities laws by ADMA Biologics, which may involve unlawful business practices by senior management, potentially impacting the company's reputation and stock price.
- Serious Allegations: A report by Culper Research on March 24, 2026, accused ADMA of 'channel stuffing,' claiming the company induced distributors to stockpile ASCENIV by offering rebates and extended payment terms, leading to misleading growth figures that could result in legal liabilities.
- Significant Stock Drop: Following the report's release, ADMA's stock price fell by $2.26, or approximately 17%, from $13.59 per share on March 23 to close at $11.33 on March 24, reflecting market concerns over the company's financial health.
- Investor Awareness Recommended: Although no lawsuit has been filed yet, the investigation is ongoing, and investors with relevant information or who purchased ADMA securities are advised to contact legal counsel to understand their rights and interests.
See More
Novartis Proposes Acquisition of Excellergy to Expand Immunology Pipeline
- Acquisition Scale: Novartis has announced a proposed acquisition of Excellergy for up to $2 billion, including upfront and milestone payments, expected to close in the second half of 2026, demonstrating the company's strategic commitment to expanding its immunology pipeline.
- Therapeutic Potential: Exl-111, a next-generation anti-IgE antibody currently in phase I trials, could significantly broaden Novartis' market reach across high-value indications such as food allergies and chronic urticaria if clinical data validate early findings.
- Enhanced Allergy Portfolio: This acquisition complements Novartis' existing allergy product line, particularly the co-promoted Xolair with Roche, further solidifying its deep expertise in IgE biology and supporting long-term growth in the immunology sector.
- Market Performance and Outlook: Novartis shares have risen 33% over the past year, significantly outperforming the industry growth of 10.1%, and despite facing generic competition for key drugs, the company is banking on key growth drivers like Kisqali and Kesimpta to support revenue growth.
See More
ADMA Biologics Faces Legal Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating ADMA Biologics, Inc. for potential violations of federal securities laws and other unlawful business practices, which could significantly impact shareholder rights.
- Short Report Allegations: On March 24, 2026, Culper Research published a short report alleging that ADMA's reported growth is fictitious, estimating a 3% revenue decline in 2025 instead of the reported 20% increase, highlighting potential financial misconduct.
- Significant Stock Price Drop: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share, indicating market concerns regarding the company's financial health.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to contact their attorneys to discuss legal options, demonstrating the firm's commitment to protecting shareholder rights and providing legal support.
See More
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: On March 24, 2026, ADMA Biologics' shares fell over 16% following a report from short seller Culper Research, which accused the company of channel stuffing and undisclosed related party distributors, undermining investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into whether ADMA violated federal securities laws, urging investors who suffered significant losses to submit their information for potential legal action.
- Financial Transparency Concerns: Culper Research highlighted a dramatic increase in ADMA's days sales outstanding (DSO), which surged to 113 days by the end of 2025 from 43 days the previous year, indicating that the company may have inflated revenues by extending payment terms, thus questioning the integrity of its financial reporting.
- Market Reaction: The sharp decline in ADMA's stock price prompted an analyst downgrade from overweight to neutral, raising concerns about the company's future financial health and potentially impacting its ability to secure financing and grow its business.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the authenticity of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly inflated revenue figures; without this scheme, the company would have faced a 3% revenue decline in 2025.
- Stock Price Plunge: The news triggered a significant decline in ADMA's stock price, dropping $3.96 or 29% over two trading days, from $13.59 on March 23 to $9.63 on March 25, indicating market concerns about the company's financial health.
- Legal Options for Investors: Investors are encouraged to contact BFA for legal support, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: ADMA Biologics saw its shares plummet over 16% on March 24, 2026, following a report from Culper Research alleging channel stuffing and undisclosed related party distributors, which undermined investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into ADMA to determine if the company violated federal securities laws, particularly regarding the compliance of its financial reporting, urging investors who suffered significant losses to submit their information.
- Financial Transparency Issues: The Culper report highlighted a dramatic increase in ADMA's days sales outstanding (DSO) from 43 days in 2024 to 113 days in 2025, suggesting the company may have inflated revenues by inducing distributors to stockpile products, thus impacting the accuracy of its financial statements.
- Analyst Downgrade: The market reacted swiftly to Culper's allegations, resulting in a significant drop in ADMA's stock price and prompting an analyst downgrade from overweight to neutral, reflecting growing concerns about the company's financial health.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Launched: Kirby McInerney LLP is investigating potential violations of federal securities laws by ADMA Biologics, which may involve unlawful business practices by senior management, potentially impacting the company's reputation and stock price.
- Serious Allegations: A report by Culper Research on March 24, 2026, accused ADMA of 'channel stuffing,' claiming the company induced distributors to stockpile ASCENIV by offering rebates and extended payment terms, leading to misleading growth figures that could result in legal liabilities.
- Significant Stock Drop: Following the report's release, ADMA's stock price fell by $2.26, or approximately 17%, from $13.59 per share on March 23 to close at $11.33 on March 24, reflecting market concerns over the company's financial health.
- Investor Awareness Recommended: Although no lawsuit has been filed yet, the investigation is ongoing, and investors with relevant information or who purchased ADMA securities are advised to contact legal counsel to understand their rights and interests.
See More
Novartis Proposes Acquisition of Excellergy to Expand Immunology Pipeline
- Acquisition Scale: Novartis has announced a proposed acquisition of Excellergy for up to $2 billion, including upfront and milestone payments, expected to close in the second half of 2026, demonstrating the company's strategic commitment to expanding its immunology pipeline.
- Therapeutic Potential: Exl-111, a next-generation anti-IgE antibody currently in phase I trials, could significantly broaden Novartis' market reach across high-value indications such as food allergies and chronic urticaria if clinical data validate early findings.
- Enhanced Allergy Portfolio: This acquisition complements Novartis' existing allergy product line, particularly the co-promoted Xolair with Roche, further solidifying its deep expertise in IgE biology and supporting long-term growth in the immunology sector.
- Market Performance and Outlook: Novartis shares have risen 33% over the past year, significantly outperforming the industry growth of 10.1%, and despite facing generic competition for key drugs, the company is banking on key growth drivers like Kisqali and Kesimpta to support revenue growth.
See More
ADMA Biologics Faces Legal Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating ADMA Biologics, Inc. for potential violations of federal securities laws and other unlawful business practices, which could significantly impact shareholder rights.
- Short Report Allegations: On March 24, 2026, Culper Research published a short report alleging that ADMA's reported growth is fictitious, estimating a 3% revenue decline in 2025 instead of the reported 20% increase, highlighting potential financial misconduct.
- Significant Stock Price Drop: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share, indicating market concerns regarding the company's financial health.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to contact their attorneys to discuss legal options, demonstrating the firm's commitment to protecting shareholder rights and providing legal support.
See More
